Testing effectiveness (Phase 2)WithdrawnNCT03221634
What this trial is testing
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
Who this might be right for
Multiple Myeloma
Merck Sharp & Dohme LLC